The CHD families analysed in this study were recruited from multiple pediatric cardiology and clinical genetics centres from the UK, USA, Canada, Germany, Belgium and Saudi Arabia, and includes families of both European and non-European ancestry (
Supplementary Table 1). In addition to single center recruitment, four multi-center cohorts were included: DDD study, UK10K project, Competence Network for Congenital Heart Defects (Germany) and published data7 (
link) from the Pediatric Cardiac Genetics Consortium (PCGC). The breakdown by centre/study is shown in
Supplementary Table 2, and by phenotype in
Supplementary Table 3. Our study focused on severely affected NS-CHD cases needing surgical intervention and S-CHD cases with clinically relevant structural heart defects. Patients were assigned to the S-CHD cohort if they showed a distinct facial gestalt or had at least one reported extra-cardiac malformation. Local Institutional review boards have approved all studies with written consent for patients or parents depending on the local requirements. Within the participating institution, the phenotype status in cases was evaluated by clinical examination, two-dimensional echocardiography, magnetic resonance imaging and cardiac catheterization, surgical or physician reports and sample description provided by deposited study files. We excluded mild cardiovascular lesions, such as an existing preterm patent ductus arteriosus and patent foramen ovale, as well as isolated extra-cardiac cardiovascular lesions, such as arterial tortuosity from the analysis. Cardiac and extra-cardiac phenotypes were translated to the current EPCC coding version (April 2015)27 (
link) and HPO terminology28 (
link) (
Supplementary Table 3). In total 1,365 trios, 68 probands from 32 multi-sibling families and 458 singleton probands were sequenced and analysed.
We also assembled a collection of 12,031 control exomes of European ancestry comprised of two datasets using similar exome capturing platforms and applying an identical processing pipeline to that used for the CHD cohorts. The first dataset incorporates 7,301 exomes (3,654 females, 3,647 males) of unaffected parents from probands not suffering from CHD in the Deciphering Developmental Disorders cohort6 (
link). The second control dataset consisted of 4,730 exomes (2,464 females, 2,266 males) of seemingly healthy blood donors as part of the INTERVAL study29 (
link).
Sifrim A., Hitz M.P., Wilsdon A., Breckpot J., Al Turki S.H., Thienpont B., McRae J., Fitzgerald T.W., Singh T., Swaminathan G.J., Prigmore E., Rajan D., Abdul-Khaliq H., Banka S., Bauer U.M., Bentham J., Berger F., Bhattacharya S., Bu'Lock F., Canham N., Colgiu I.G., Cosgrove C., Cox H., Daehnert I., Daly A., Danesh J., Fryer A., Gewillig M., Hobson E., Hoff K., Homfray T., Kahlert A.K., Ketley A., Kramer H.H., Lachlan K., Lampe A.K., Louw J.J., Manickara A.K., Manase D., McCarthy K.P., Metcalfe K., Moore C., Newbury-Ecob R., Omer S.O., Ouwehand W.H., Park S.M., Parker M.J., Pickardt T., Pollard M.O., Robert L., Roberts D.J., Sambrook J., Setchfield K., Stiller B., Thornborough C., Toka O., Watkins H., Williams D., Wright M., Mital S., Daubeney P.E., Keavney B., Goodship J., Abu-Sulaiman R.M., Klaassen S., Wright C.F., Firth H.V., Barrett J.C., Devriendt K., FitzPatrick D.R., Brook J.D, & Hurles M. (2016). Distinct genetic architectures for syndromic and nonsyndromic congenital heart defects identified by exome sequencing. Nature genetics, 48(9), 1060-1065.